SCHEMBL12766723

SCHEMBL12766723

Cc1c(O)c(C=O)c(C)c2cocc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 3/20 0.38
▸ BCL2 P10415 2/20 0.38
▸ IGF1R P08069 2/20 0.36
▸ SRC P12931 2/20 0.36
▸ AXL P30530 2/20 0.36
▸ PTK2 Q05397 2/20 0.36
▸ AURKB Q96GD4 2/20 0.36
▸ ALK Q9UM73 2/20 0.36
▸ HDAC3 O15379 1/20 0.36
▸ NUAK1 O60285 1/20 0.36
▸ MET P08581 1/20 0.36
▸ PIM1 P11309 1/20 0.36
▸ AKT1 P31749 1/20 0.36
▸ KDR P35968 1/20 0.36
▸ NEK2 P51955 1/20 0.36
▸ PLK1 P53350 1/20 0.36
▸ HDAC4 P56524 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ PKN1 Q16512 1/20 0.36
▸ HDAC7 Q8WUI4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12766724 0.76 CYP3A4 (0.37) MCL1BCL2IGF1RSRCAXL
SCHEMBL27881770 0.72 LDHA (0.32) LDHAESR1LDHB
SCHEMBL21929661 0.71 MAOB (0.44) MCL1BCL2IGF1RSRCAXL
SCHEMBL11953498 0.71 MAOB (0.44) MCL1BCL2IGF1RSRCAXL
SCHEMBL12766729 0.71 ERN1 (0.36) IGF1RSRCAXLPTK2AURKB
SCHEMBL1527179 0.70 IGF1R (0.43) MCL1BCL2IGF1RSRCAXL
SCHEMBL8434028 0.68 MAOB (0.45) MCL1BCL2IGF1RSRCAXL
SCHEMBL28118679 0.68 IGF1R (0.42) MCL1BCL2IGF1RSRCAXL
SCHEMBL13018018 0.67 PADI4 (0.35) IGF1RSRCAXLPTK2AURKB
SCHEMBL19463560 0.64 CYP3A4 (0.53) IGF1RSRCAXLPTK2AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9981901-B2 IRE-1α inhibitors FOSUN ORINOVE PHARMATECH, INC. (CN) 2018-05-29 — — US disclosed
US-20170152206-A1 IRE-1alpha INHIBITORS FOSUN ORINOVE PHARMATECH, INC. (CN) 2017-06-01 — — US disclosed
US-9546149-B2 IRE-1α inhibitors MANNKIND CORPORATION (US) 2017-01-17 — — US disclosed
US-20160168116-A1 IRE-1alpha Inhibitors FOSUN ORINOVE PHARMATECH, INC. (CN) 2016-06-16 — — US disclosed
US-9241942-B2 IRE-1α inhibitors MANNKIND CORPORATION (US) 2016-01-26 — — US disclosed
US-20140080832-A1 IRE-1alpha INHIBITORS MANNKIND CORPORATION (US) 2014-03-20 — — US disclosed
US-20110065162-A1 IRE-1alpha INHIBITORS MANNKIND CORPORATION (US) 2011-03-17 — — US disclosed
US-7858666-B2 inositol requiring enzyme 1 (IRE-1 alpha) inhibitors such as 2-hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, relieve protein folding stress by enhancing molecular chaperone activity and protects cells from stress induced apoptosis; autoimmune diseases; anticancer; viricides MANNKIND CORPORATION (US) 2010-12-28 — — US disclosed
US-20090186893-A1 IRE-1alpha INHIBITORS MANNKIND CORPORATION (US) 2009-07-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170152206-A1 IRE-1alpha INHIBITORS XBP1, DDIT3, ERN1 MCL1 443/4885BCL2 1632/4885IGF1R 384/4885
US-20160168116-A1 IRE-1alpha Inhibitors XBP1, DDIT3, ERN1 MCL1 443/4885BCL2 1632/4885IGF1R 384/4885
US-20140080832-A1 IRE-1alpha INHIBITORS XBP1, DDIT3, ERN1 MCL1 443/4885BCL2 1632/4885IGF1R 384/4885
US-20090186893-A1 IRE-1alpha INHIBITORS XBP1, DDIT3, ERN1 MCL1 443/4885BCL2 1632/4885IGF1R 384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback